Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

Kathryn E. Ware, Santosh Gupta, Jared Eng, Gabor Kemeny, Bhairavy Puviindran, Wen‐Chi Foo, Lorin Crawford, R. Garland Almquist, Daniella Runyambo, Beatrice C. Thomas, Maya U. Sheth, Anika Agarwal, Mariaelena Pierobon, Emanuel F. Petricoin, David L. Corcoran, Jennifer A. Freedman, Steven R. Patierno, Tian Zhang, Simon G. Gregory, Zoi E. Sychev, Justin M. Drake, Andrew J. Armstrong, Jason A. SomarellibioRxiv 2020 · DOI

TL;DR

This paper reveals that prostate cancer cells, when developing resistance to hormone therapy (specifically enzalutamide), undergo "convergent evolution" by activating the p38/MAPK pathway. This pathway drives key survival, metastatic, and immune-evasive phenotypes, suggesting p38 inhibition as a potential therapeutic strategy.

What Problem Does This Paper Address?

Prostate cancer cells often develop resistance to androgen receptor (AR) targeted therapies like enzalutamide, leading to disease progression. While resistance mechanisms are diverse, the underlying common drivers and evolutionary strategies employed by cancer cells to adapt to these challenging environments remain incompletely understood. This paper investigates how cancer cells adapt to enzalutamide treatment by drawing parallels to ecological principles of survival in resource-depleted environments.

Methods

The researchers developed several enzalutamide-resistant (enzaR) prostate cancer cell lines through chronic exposure to increasing doses of enzalutamide. They employed a multi-omics approach, including RNA-Seq, reverse phase protein array (RPPA), and immunohistochemistry, to identify common molecular changes and pathways activated in these resistant cells. They also utilized CRISPR/Cas9 gene editing to knock out or overexpress p38 in cell lines and conducted in vivo xenograft studies to assess the therapeutic potential of p38 inhibition.

Datasets

The study utilized data from:

  • In-house generated enzalutamide-resistant (enzaR) cell lines: Four distinct cell lines (LNCaP-enzaR, CS2-enzaR, LN95-enzaR, and MDA-PCa-2b-enzaR) were developed.
  • The Cancer Genome Atlas (TCGA): Used to analyze correlations between Snail and PD-L1 expression in prostate cancer tissues.
  • Published phosphoproteomic datasets: Used for kinase substrate enrichment analysis.
  • Prostate cancer patient samples: 30 localized and 20 metastatic samples were used for immunohistochemistry.

Key Insights and Ideas

  • Cancer cells as ecological adapters: The study frames cancer cell adaptation to therapy as analogous to natural populations facing resource depletion, employing strategies like dormancy, migration, and predator avoidance.
  • Convergent evolution of p38/MAPK: Despite diverse genetic alterations in resistant cells, the p38/MAPK pathway consistently emerges as a key activated signaling node, suggesting a convergent evolutionary strategy.
  • p38 as a master regulator: The p38 pathway appears to orchestrate multiple pro-survival, pro-metastatic, and immune-evasive phenotypes, linking seemingly disparate resistance mechanisms.
  • Snail and PD-L1 as downstream effectors: The study identifies Snail as a key mediator of p38's effects, leading to increased PD-L1 expression and immune evasion.

Key Results

  • Enzalutamide-resistant cells consistently activate the p38/MAPK pathway.
  • p38 activation drives three key phenotypes: pro-survival (dormancy), metastasis (via Snail upregulation), and immune evasion (via PD-L1 upregulation).
  • Inhibition of p38 significantly reduced cell proliferation in enzaR cell lines and tumor growth in vivo.
  • p38 activation promotes sustained AR signaling in the presence of enzalutamide.
  • Clinical data showed increased p38 and Snail expression in metastatic prostate cancer tissues.

Limitations and Future Work

  • Model System Limitations: While the developed enzaR cell lines recapitulate some aspects of clinical resistance, they may not fully represent the heterogeneity of human tumors.
  • Mechanistic Details: While the study establishes p38 as a central driver, further detailed mechanistic investigations into how p38 regulates AR activity and other downstream pathways could be beneficial.
  • Therapeutic Translation: The authors suggest that targeting the p38 pathway, potentially in combination with other therapies, warrants further clinical investigation for treating hormone-therapy resistant prostate cancer. Future work could focus on optimizing p38 inhibitors and exploring combination strategies.

Summary updated

Abstract

Summary Adaptation of cancer cells to targeted therapy follows ecological paradigms observed in natural populations that encounter resource depletion and changing environments, including activation of pro-survival mechanisms, migration to new locations, and escape of predation. We identified the p38 MAPK pathway as a common molecular driver of these three responses during the adaptation to hormone therapy resistance in prostate cancer. The p38 pathway is activated in therapy-resistant cells and mechanistically drives these three convergent responses through sustained AR activity, enhanced invasion and metastasis, and immune evasion. Targeting p38 signaling may represent a new therapeutic strategy to treat men with metastatic, hormone therapy-resistant prostate cancer.
BibTeX
@misc{ware2020convergent,
  author = {Kathryn E. Ware and Santosh Gupta and Jared Eng and Gabor Kemeny and Bhairavy Puviindran and Wen‐Chi Foo and Lorin Crawford and R. Garland Almquist and Daniella Runyambo and Beatrice C. Thomas and Maya U. Sheth and Anika Agarwal and Mariaelena Pierobon and Emanuel F. Petricoin and David L. Corcoran and Jennifer A. Freedman and Steven R. Patierno and Tian Zhang and Simon G. Gregory and Zoi E. Sychev and Justin M. Drake and Andrew J. Armstrong and Jason A. Somarelli},
  title = {{Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes}},
  year = {2020},
  doi = {10.1101/2020.04.22.050385},
  howpublished = {bioRxiv},
}

Loading related content...

Figure